Oxitope Pharma B.V.

Ascendis Pharma A/S has two approved products and plans to submit a third drug candidate for approval later this year from its endocrinology rare disease portfolio. It also has two clinical-stage can

Merging two companies and securing a €75m ($81m) series A venture round is not an unimpressive achievement, particularly when the combined group is yet to achieve proof of concept, and is active in th